All In Biotech

NDA 021882 · Novartis

Exjade

Deferasirox · Oral · Iron Chelator

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jan 17, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Nov 2, 2005

Approved uses

7

Original approval plus efficacy supplements

Registered trials

97

15 Phase 3, 2 recruiting

FAERS reports

22,940

20,778 serious, 7,078 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RENAL FAILURE, HEPATIC FAILURE, and GASTROINTESTINAL HEMORRHAGE Renal Failure Exjade can cause acute renal failure and death, particularly in patients with comorbidities and those who are in the advanced stages of their hematologic disorders. Evaluate baseline renal function prior to starting or increasing Exjade dosing in all patients. Exjade is contraindicated in adult and pediatric patients with eGFR less than 40 mL/min/1.73 m 2 . Measure serum creatinine in duplicate prior to initiation of therapy. Monitor renal function at least monthly. For patients with baseline renal impairment or increased risk of acute renal failure, monitor renal function weekly for the first month, then at least monthly. Reduce the starting dose in patients with preexisting renal disease. During therapy, increase the frequency of monitoring and modify the dose for patients with an increased risk of...

What it is approved for

From the label in effect Jan 28, 2026.

Exjade is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Exjade is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L. ( 1.2 ) Limitations of Use: The safety and efficacy of Exjade when administered with other iron chelation therapy have not been established. ( 1.3 ) 1.1 Treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload) Exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. 1.2 Treatment of Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia Syndromes Exjade is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L. 1.3 Limitations of Use The safety and efficacy of Exjade when administered with other iron chelation therapy have not been established.

Mechanism: Exjade (deferasirox) is an orally active chelator that is selective for iron (as Fe 3+ ). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • EXJADE · DEFERASIROX 125MG · TABLET, FOR SUSPENSION, ORAL · Prescription · TE AB
  • EXJADE · DEFERASIROX 250MG · TABLET, FOR SUSPENSION, ORAL · Prescription · TE AB
  • EXJADE · DEFERASIROX 500MG · TABLET, FOR SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Deferasirox" as an intervention, any sponsor and status, largest first.

All 97 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death4,237
  • diarrhoea2,082
  • sickle cell anaemia with crisis1,617
  • pyrexia1,362
  • nausea1,273
  • haemoglobin decreased1,252
  • pneumonia1,152
  • serum ferritin increased1,072
  • malaise1,020
  • vomiting1,003
  • fatigue980
  • abdominal pain829

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
2006379
2007336
2008402
20092,043
20102,487
20113,027
20122,694
2013831
20141,693
20152,168
20161,311
2017941
2018750
2019559
2020553
2021552
2022656
2023458
2024452
2025373
2026274

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Exjade (Deferasirox)

2024 spending

$3.2M

Beneficiaries

46

232 claims

Per beneficiary

$68,983

$159.61 per unit

View as table
YearSpending
2020$14,718,471
2021$8,578,931
2022$4,221,647
2023$2,925,424
2024$3,173,237

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 182 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.